Cost-Benefit Analysis of Kidney Donor Compensation, Disincentive Removal, and Federal Kidney Initiatives
1. Executive Summary & Policy Synthesis
Across academic health economics and federal regulatory evaluations, increasing kidney transplantation delivers massive returns in societal welfare, life expectancy, and budgetary savings by taking end-stage renal disease (ESRD) patients off chronic dialysis.
The Disincentive Removal Model (McCormick, Held et al., 2019, JASN): Focuses on neutralizing the financial, physical, and psychological barriers facing living donors (estimated at ~$38,000 per donor). With an initial public outlay of ~$520 million per year, it yields $1.3 billion per year in net taxpayer savings and $13.7 billion to $14 billion annually in net societal welfare.
The Comprehensive Donor Compensation Model (Held et al., 2016, AJT): Examines direct federal compensation of $45,000 per living donor to eliminate the kidney shortage entirely. In steady-state (~35,000 transplants/year), this program generates $14.1 billion annually in net taxpayer savings and $65.6 billion per year in net societal welfare, achieving a 3.0 to 1 benefit-cost ratio for society and 1.7 to 1 for taxpayers.
The Federal Initiative Benchmark (HHS/ASPE Report, Oct 20, 2026): Evaluates the empirical acceleration in kidney transplants following Executive Order 13879 (Advancing American Kidney Health). It shows that policy-associated growth (1,055 to 2,110 additional transplants/year) yields $103 billion to $206 billion in cumulative economic benefits from 2019 to 2040. Each transplant occurring in 2026 generates approximately $4.7 million in total economic value ($3.9M in mortality reductions, $0.68M in quality-of-life gains, and $0.12M in dialysis time savings).
2. Federal Policy Evaluation: The Advancing American Kidney Health Initiative (HHS/ASPE, 2026)
The Department of Health and Human Services (HHS) Office of the Assistant Secretary for Planning and Evaluation (ASPE) evaluated the real-world and projected health and economic impacts of Executive Order 13879, which reformed Organ Procurement Organization (OPO) performance standards and modernized allocation metrics.
A. Transplant Growth Trends (2002–2025)
Historical vs. Post-EO Growth: Between 2009 and 2018, annual kidney transplants grew at a compound annual growth rate of 2.6%. Following the 2019 initiative, growth accelerated to 2.8% from 2019 to 2025.
Deceased vs. Living Donors: Overall transplants rose from 14,781 in 2002 to 27,574 in 2025. This increase was driven almost exclusively by deceased-donor transplantation (increasing from 8,540 to 21,052/year), supported by donation after circulatory death (DCD) and normothermic regional perfusion (NRP). Living-donor transplants remained flat and stagnant, fluctuating narrowly between 5,200 and 6,900 per year—underscoring the acute need for living donor policy interventions.
B. Health Gains and Cumulative Economic Benefits (2019–2040)
Using a 3% discount rate and standard HHS regulatory impact methods, ASPE modeled the cumulative returns across two policy counterfactuals:
Metric (Cumulative 2019–2040)Conservative ScenarioOptimistic Scenario
Conservative Scenario (Cumulative 2019–2040)
Additional Transplants per Year: +1,055 / year
Total Cumulative Additional Transplants: 23,214
Life-Years Gained (Mortality Benefits): 147,410 life-years
QALYs Gained (Morbidity Benefits): 21,821 QALYs
Economic Benefits (Low VSLY: $283,454): $57 Billion
Economic Benefits (Central VSLY: $607,402): $103 Billion
Economic Benefits (High VSLY: $924,602): $148 Billion
Optimistic Scenario (Cumulative 2019–2040)
Additional Transplants per Year: +2,110 / year
Total Cumulative Additional Transplants: 46,428
Life-Years Gained (Mortality Benefits): 294,819 life-years
QALYs Gained (Morbidity Benefits): 43,643 QALYs
Economic Benefits (Low VSLY: $283,454): $114 Billion
Economic Benefits (Central VSLY: $607,402): $206 Billion
Economic Benefits (High VSLY: $924,602): $295 Billion
Direct Side-by-Side Text Comparison:
Additional Transplants per Year: Conservative: +1,055 / year | Optimistic: +2,110 / year
Total Cumulative Additional Transplants: Conservative: 23,214 | Optimistic: 46,428
Life-Years Gained (Mortality Benefits): Conservative: 147,410 life-years | Optimistic: 294,819 life-years
QALYs Gained (Morbidity Benefits): Conservative: 21,821 QALYs | Optimistic: 43,643 QALYs
Economic Benefits (Low VSLY: $283,454): Conservative: $57 Billion | Optimistic: $114 Billion
Economic Benefits (Central VSLY: $607,402): Conservative: $103 Billion | Optimistic: $206 Billion
Economic Benefits (High VSLY: $924,602): Conservative: $148 Billion | Optimistic: $295 Billion
C. Total Economic Value Per Transplant ($4.7 Million in 2026)
ASPE calculated the total economic benefit per transplant occurring in 2026 at ~$4.7 million, broken down across three dimensions:
Mortality Reductions ($3.9 Million): An average 10-year gain in life expectancy equals 6.35 discounted life-years (at a 3% rate); valued at the central Value of a Statistical Life Year (VSLY) of $607,402, this generates $3.9 million per transplant.
Quality-of-Life / Morbidity Gains ($0.68 Million): Transplant recipients experience a mean utility improvement of 0.11 over dialysis, yielding 0.94 discounted QALYs; valued at a central Value per QALY (VQALY) of $722,068, this confers $680,000 per recipient.
Time Savings from Avoiding Dialysis ($0.12 Million): Dialysis requires ~4.5 hours per session (including travel), three times weekly, totaling ~671 hours saved per year (~5,720 present value hours over a recipient's lifetime); at a standard regulatory time value of $20.27/hour, this returns $120,000 in direct patient time savings.
3. Removing Donor Disincentives (JASN, 2019)
A. The Seven Disincentives Facing Living Donors
McCormick, Held, Chertow, Peters, and Roberts identified seven discrete disincentives that place a net burden of $37,745 on every living kidney donor (2017 dollars):
Travel and Lodging ($3,122): Direct out-of-pocket expenses.
Remedy: Expand NLDAC to donors across all income levels.
Lost Wages & Uncompensated Income ($5,118): Uncompensated lost wages ($1,923) plus two-thirds of used sick leave, vacation time, and disability benefits ($3,195).
Remedy: Provide a $5,000 refundable tax credit (or up to $10,000 with documentation).
Home & Dependent Care ($5,592): Lost household productivity and dependent caregiving during recovery.
Remedy: Provide a $6,000 refundable tax credit.
Surgical Mortality Risk ($1,860): Calculated from a 3.1 per 10,000 surgical mortality rate applied to a $5M value of statistical life, plus 20% administration.
Remedy: Provide a government-funded $5 million short-term life insurance policy.
Pain and Discomfort ($6,414): Accounting for surgical trauma, complications (affecting 7.3% to 16.8% of donors), and post-op fatigue.
Remedy: Provide a $6,500 refundable tax credit.
Long-Term Health Risks ($7,910): Covers the elevated risk of end-stage renal disease ($6,328) and insurability risks.
Remedy: Comprehensive lifetime insurance covering disability, health complications, and life insurance obstacles.
Option Value for Loved Ones ($7,728): The psychological cost of parting with a spare kidney that a child, spouse, or friend might need in the future.
Remedy: A family organ voucher guaranteeing priority allocation if a designated loved one develops ESRD (budget cost: $0).
B. National Budget and Welfare Impact
Supply Response: Neutralizing these barriers is projected to add 11,517 living donors annually in the base case (+938 from deceased donor voucher incentives), cutting the transplant waiting list in half in approximately 4 years.
Fiscal Return: At an outlay of $30,017 per donor (~$520 million annually), gross taxpayer savings from avoiding dialysis reach $1.8 billion, generating $1.3 billion per year in net taxpayer savings.
Break-Even Point: Taxpayers save money as long as the policy induces just 326 additional living donors per year (less than 3% of the base-case estimate).
4. Comprehensive Government Compensation (AJT, 2016)
Held, McCormick, Ojo, and Roberts evaluated the macroeconomic impact of offering direct compensation ($45,000 per living donor and $10,000 to deceased donor estates) to end the organ shortage permanently:
A. Per-Recipient Lifetime Economics (Discounted at 3%)
Life Expectancy: Increases from 12.3 years on dialysis to 24.9 years with transplantation in steady-state (+9.9 unadjusted life-years; +6.7 discounted QALYs).
Recipient Welfare Gain: Valuing a QALY at $200,000 yields $1,335,000 in lifetime welfare per patient.
Dialysis Savings: Avoiding chronic dialysis saves $1,454,000 per recipient over a lifetime.
Total Procedure & Compensation Costs: Initial and discounted future transplants plus donor payments total $309,000 ($236k procedure costs + $73k discounted donor payments).
Net Lifetime Taxpayer Savings: Saves taxpayers $403,000 net per recipient.
B. Aggregate Annual Impact (Steady State at 35,000 Transplants/Year)
Gross Dialysis Cost Avoidance: $50.9 billion per year.
Total Outlay for Donor Compensation: $2.6 billion per year.
Net Taxpayer Savings: Expands from $2.6 billion/year under the status quo to $14.1 billion annually.
Net Societal Welfare: Triples from $19.8 billion/year to $65.6 billion annually.
Benefit-to-Cost Ratio: 3.0 to 1 for society; 1.7 to 1 for taxpayers.
5. Comparative Policy Matrix
Disincentive Removal (JASN, 2019)
Primary Mechanism: Offset 7 discrete donor costs via refundable tax credits & insurance
Donor Focus: Living donors (+ family voucher for deceased)
Transplant Volume Impact: +12,455 / year (cuts waiting list in half in 4 yrs)
Per-Transplant Value: $146,000 net taxpayer savings; $1.13M societal welfare
Annual Taxpayer Budget Impact: +$1.3 Billion net savings / year
Annual / Total Societal Benefit: +$13.7 Billion / year
Direct Compensation (AJT, 2016)
Primary Mechanism: $45,000 compensation package per living donor
Donor Focus: Living and deceased donors
Transplant Volume Impact: +17,500 / year (eliminates waiting list in 5 yrs)
Per-Transplant Value: $403,000 net taxpayer savings; $1.87M societal welfare
Annual Taxpayer Budget Impact: +$14.1 Billion net savings / year
Annual / Total Societal Benefit: +$65.6 Billion / year
Executive Order 13879 (ASPE, 2026)
Primary Mechanism: Administrative OPO metrics & regulatory benchmarks
Donor Focus: Primarily deceased donors (DCD, NRP)
Transplant Volume Impact: +1,055 to +2,110 / year
Per-Transplant Value: $4.7M total economic benefit per transplant (in 2026)
Annual Taxpayer Budget Impact: Net lifetime medical impact: -$12k to +$36.7k
Annual / Total Societal Benefit: +$103B to +$206B (cumulative 2019–2040)
Direct Side-by-Side Text Comparison:
Primary Mechanism:
Disincentive Removal: Offset 7 discrete donor costs via refundable tax credits & insurance
Direct Compensation: $45,000 compensation package per living donor
Executive Order 13879: Administrative OPO metrics & regulatory benchmarks
Donor Focus:
Disincentive Removal: Living donors (+ family voucher for deceased)
Direct Compensation: Living and deceased donors
Executive Order 13879: Primarily deceased donors (DCD, NRP)
Transplant Volume Impact:
Disincentive Removal: +12,455 / year (cuts waiting list in half in 4 yrs)
Direct Compensation: +17,500 / year (eliminates waiting list in 5 yrs)
Executive Order 13879: +1,055 to +2,110 / year
Per-Transplant Value:
Disincentive Removal: $146,000 net taxpayer savings; $1.13M societal welfare
Direct Compensation: $403,000 net taxpayer savings; $1.87M societal welfare
Executive Order 13879: $4.7M total economic benefit per transplant (in 2026)
Annual Taxpayer Budget Impact:
Disincentive Removal: +$1.3 Billion net savings / year
Direct Compensation: +$14.1 Billion net savings / year
Executive Order 13879: Net lifetime medical impact: -$12k to +$36.7k
Annual / Total Societal Benefit:
Disincentive Removal: +$13.7 Billion / year
Direct Compensation: +$65.6 Billion / year
Executive Order 13879: +$103B to +$206B (cumulative 2019–2040)
6. Strategic Takeaways for Kidney Health Policy
Deceased Donor Reforms Cannot Solve the Shortage Alone: ASPE's data demonstrates that administrative OPO reforms successfully accelerated deceased donation, but living donation remained flat (5,200–6,900/year). Closing the gap requires addressing living donor financial disincentives.
Uncontested Fiscal Headroom: Under ASPE’s regulatory methodology, a single transplant produces $4.7 million in economic value. Under Held et al., donor compensation could rise to $375,000 per kidney before taxpayers stop saving money over dialysis, and up to $1.2 million per kidney before society stops realizing a net economic gain.
Rebutting Concerns Over Equity: The current organ shortage disproportionately harms low-income and minority patients, who are overrepresented on the waiting list. Because Medicare covers kidney failure treatment, eliminating the shortage provides lower-income patients with millions of dollars in health, longevity, and quality of life at little to no out-of-pocket expense.